HeartBeam (NASDAQ: BEAT), a cardiac technology company, has developed the first and only 3D-vector electrocardiogram (“VECG”) platform for timely heart attack detection. The company today announced that the United States Patent and Trademark Office has allowed its patent for a 12-lead electrocardiogram (“ECG”) smartwatch-based monitor intended for detection of heart attacks and complex cardiac arrhythmias. The innovation expands HeartBeam’s growing intellectual property portfolio enabling 12-lead ECG diagnostics outside of a medical setting. “The breakthrough inventions protected by this patent enable our proprietary 3D ECG technology to be built into a smartwatch, eliminating the need for a dedicated ECG device while offering a 12-lead ECG capability enabling heart attack and complex arrhythmia detection,” said HeartBeam CEO and Founder Branislav Vajdic, PhD. “This patent may prove to be one of the most valuable patents in our rich and growing patent portfolio and, together with our 12-lead ECG patch patent, I believe, will have a disruptive effect on these existing multibillion-dollar fast-growing markets.”
To view the full press release, visit https://ibn.fm/axqBX
About HeartBeam Inc.
HeartBeam is a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere. By applying a suite of proprietary algorithms to simplify vector electrocardiography (“VECG”), the HeartBeam platform enables patients and their clinicians to determine if symptoms are due to a heart attack, quickly and easily, so care can be expedited, if required. HeartBeam has two patented products in development. HeartBeam AIMI(TM) is software for acute care settings that provides a 3D comparison of baseline and symptomatic 12-lead ECG to more accurately identify a heart attack. HeartBeam AIMIGo(TM) is the first and only credit card-sized 12-lead output ECG device coupled with a smart phone app and cloud-based diagnostic software system to facilitate remote heart attack detection. HeartBeam AIMI and AIMIGo have not yet been cleared by the U.S. Food and Drug Administration (“FDA”) for marketing in the USA or other geographies. For more information, visit www.HeartBeam.com.
NOTE TO INVESTORS: The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information please visit https://www.biomedwire.com
BioMedWire is part of the InvestorBrandNetwork